Literature DB >> 30753585

Salvage surgery for small cell lung cancer after chemoradiotherapy.

Keita Nakanishi1, Tetsuya Mizuno1, Noriaki Sakakura1, Hiroaki Kuroda1, Junichi Shimizu2, Toyoaki Hida2, Yasushi Yatabe3, Yukinori Sakao1.   

Abstract

There are few reports on the use of salvage surgery for small cell lung cancer (SCLC). Five patients who underwent resection of post-chemoradiotherapy residual lesion/local reprogression of SCLC between 2005 and 2017 were included in the study. We retrospectively reviewed their surgical outcomes and prognosis to assess the feasibility and potential efficacy of salvage surgery. Indications for salvage surgery were local reprogression (four patients) and residual lesion (one patient) with ycN0 disease. Complete pathological resection was achieved in four patients; however, malignant pleural effusion was diagnosed in one patient after the surgery. Morbidity and mortality rates were 0%. Estimated 5-year survival rate was 67%. Recurrence and death after surgery occurred only in the patient with malignant pleural effusion. We demonstrate the feasibility of salvage surgery in SCLC. In carefully-selected patients, especially those without lymph node involvement, salvage surgery may provide effective local control and favorable survival outcomes.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chemoradiotherapy; lung resection; reprogression; salvage surgery; small cell lung cancer

Mesh:

Year:  2019        PMID: 30753585     DOI: 10.1093/jjco/hyz010

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

Review 1.  The current role of surgery and SBRT in early stage of small cell lung cancer.

Authors:  Núria Farré; José Belda-Sanchis; Mauro Guarino; Laura Tilea; Jady Vivian Rojas Cordero; Elisabeth Martínez-Téllez
Journal:  J Clin Transl Res       Date:  2021-02-17

2.  Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC.

Authors:  Pieter J M Joosten; Toon A Winkelman; David J Heineman; Sayed M S Hashemi; Idris Bahce; Suresh Senan; Marinus A Paul; Koen J Hartemink; Max Dahele; Chris Dickhoff
Journal:  JTO Clin Res Rep       Date:  2021-04-15

Review 3.  New perspectives in the management of small cell lung cancer.

Authors:  Cristina Pangua; Jacobo Rogado; Gloria Serrano-Montero; José Belda-Sanchís; Beatriz Álvarez Rodríguez; Laura Torrado; Nuria Rodríguez De Dios; Xabier Mielgo-Rubio; Juan Carlos Trujillo; Felipe Couñago
Journal:  World J Clin Oncol       Date:  2022-06-24

4.  Upregulated miRNA-182-5p expression in tumor tissue and peripheral blood samples from patients with non-small cell lung cancer is associated with downregulated Caspase 2 expression.

Authors:  Lu Yang; Ye Dou; Zhuxin Sui; Hui Cheng; Xia Liu; Qinglu Wang; Peifu Gao; Yin'e Qu; Ming Xu
Journal:  Exp Ther Med       Date:  2019-10-02       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.